Mazyar Shadman, MD, MPH

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss ongoing trials and future treatment directions for chronic lymphocytic leukemia.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss real-world safety data for BTK inhibitors in chronic lymphocytic leukemia from EHA 2024.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss matching-adjusted indirect comparisons of BTK inhibitors in chronic lymphocytic leukemia.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss findings from the SEQUOIA trial of zanubrutinib in treatment-naive chronic lymphocytic leukemia.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss how to use data for BTK inhibitors to inform clinical decisions in chronic lymphocytic leukemia.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, on factors for selecting a BTK inhibitor or a venetoclax-based regimen in chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the rationale for combining sonrotoclax plus zanubrutinib for treatment-naive chronic lymphocytic leukemia.

This is an evaluation of the results of a network meta-analysis covering the comparative efficacy of bruton tyrosine kinase Inhibitors in relapse/refractory chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses results from a network meta-analysis on the comparative efficacy of BTK inhibitors in relapsed/refractory CLL.

Mazyar Shadman, MD, MPH, discusses preliminary long-term findings from the evaluation of zanubrutinib in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were intolerant to ibrutinib and/or acalabrutinib.

Mazyar Shadman, MD, MPH, discusses the efficacy and safety of zanubrutinib in chronic lymphocytic leukemia, as well as data derived from the agents use which supports the regulatory approval of zanubrutinib in this patient population.

Mazyar Shadman, MD, MPH, discusses the exploration of MB-106, a third-generation CD20-targeted autologous CAR T-cell therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the efficacy of MB-106, a CD20-targeted CAR T-cell therapy in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the methods utilized in an ongoing phase 1/2 trial evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the safety profile of MB-106, a third-generation, CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses the emergence of third-generation BTK inhibitors in chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses considerations for BTK inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses continuous vs time-limited treatments for patients with chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses the role of minimal residual disease in chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses the potential for CAR T-cell therapy in patients with high-risk chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses the potential utility of LOXO-305 in chronic lymphocytic leukemia.

Mazyar Shadman, MD, shares treatment considerations for patients with chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, discusses next steps for CAR T-cell therapy in diffuse large B-cell lymphoma.